文献类型：期刊文献

英文题名：Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice

作者：Cheng, Mingrong[2,4];Liu, Zheng[3];Wan, Tao[1];He, Bing[4];Zha, Bingbing[5];Han, Jiang[2];Chen, Houxiang[1];Yang, Fengxiao[1];Li, Qing[6];Wang, Wei[2];Xu, Hongzhi[4];Ye, Tao[4]

机构：[1]Wuhan Univ Technol, Biomed Mat & Engn Ctr, Wuhan 430070, Peoples R China;[2]Shanghai Pudong New Area, Zhoupu Hosp, Dept Gen Surg, Shanghai, Peoples R China;[3]Shaoxing Univ, Coll Med, Dept Basic Med, Shao Xing, Peoples R China;[4]Fudan Univ, Dept Gen Surg, Shanghai Peoples Hosp 5, Shanghai 200433, Peoples R China;[5]Fudan Univ, Dept Endocrine, Shanghai Peoples Hosp 5, Shanghai 200433, Peoples R China;[6]Pujiang Hosp Shanghai, Peoples Hosp 5, Dept Med Genet, Shanghai, Peoples R China

年份：2012

卷号：13

期号：14

起止页码：1407

外文期刊名：CANCER BIOLOGY & THERAPY

收录：SCI-EXPANDED(收录号：WOS:000312212200008)、、Scopus(收录号：2-s2.0-84870704829)、WOS

基金：This work was supported by Natural Science Foundation of Shanghai (09ZR1424700 and 114119a4700); Minhang District Natural Science Foundation of Shanghai (2009MHZ085); Minhang District Public Health Bureau Foundation of Shanghai (2009MW28).

语种：英文

外文关键词：galactosylated chitosan; nanoparticles; 5-fluorouracil; hepatocellular cancer; pharmacokinetics; apoptosis

外文摘要：Biodegradable polymer nanoparticle drug delivery systems are characterized by targeted drug delivery, improved pharmacokinetic and biodistribution, enhanced drug stability and lowered side effects; these drug delivery systems are widely used for delivery of cytotoxic agents. The galactosylated chitosan (GC)/5-fluorouracil (5-FU) nanoparticle is a nanomaterial made by coupling GC, a polymer known to have the advantages described above, and 5-FU. The GC/5-FU nanoparticle is a sustained release system, it was showed that the peak time, half-life time, mean residence time (MRT) and area of under curve (AUC) of GC/5-FU were longer or more than those of the 5-FU group, but the maximum concentration (Cmax) was lower. The distribution of GC/5-FU in vivo revealed the greatest accumulation in the hepatic cancer tissues, and the hepatic cell was the target of the nanoparticles. Toxicology research showed that the toxicity of GC-5-FU was lower than that of 5-FU in mice. In vivo experiments showed that GC/5-FU can significantly inhibit tumor growth in an orthotropic liver cancer mouse model. GC/5-FU treatment can significantly lower the tumor weight and increase the survival time of mice when compared with 5-FU treatment alone. Flow cytometry and the TUNEL assay revealed that compared with 5-FU, GC/5-FU caused higher rates of G(0)-G(1) arrest and apoptosis in hepatic cancer cells.